was read the article
array:23 [ "pii" => "S0121812323000580" "issn" => "01218123" "doi" => "10.1016/j.rcreu.2023.07.001" "estado" => "S300" "fechaPublicacion" => "2024-04-01" "aid" => "2064" "copyright" => "Asociación Colombiana de Reumatología" "copyrightAnyo" => "2024" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Rev Colomb Reumatol. 2024;31 Supl 1:S15-S25" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:17 [ "pii" => "S0121812323000592" "issn" => "01218123" "doi" => "10.1016/j.rcreu.2023.07.002" "estado" => "S300" "fechaPublicacion" => "2024-04-01" "aid" => "2066" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Rev Colomb Reumatol. 2024;31 Supl 1:S26-S34" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review Article</span>" "titulo" => "An overview of screening, treatment, and next steps in research in rheumatoid arthritis interstitial lung disease" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S26" "paginaFinal" => "S34" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Una visión general del cribado, el tratamiento y los próximos pasos en la investigación de la enfermedad pulmonar intersticial por artritis reumatoide" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 963 "Ancho" => 2508 "Tamanyo" => 167621 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">(A) Impact of immunosuppression on predicted trajectory of forced vital capacity (FVC) % predicted. The pre-treatment trend in FVC is shown from time −24 months to time 0 when RA-ILD specific treatment was initiated. The pre-treatment trend (blue dotted line) is projected forward from time 0 to +24 months and compared to the observed FVC trend after treatment initiation. After 12 months of treatment, there was a significant increase in FVC % predicted compared to the projected trend without treatment [+3.90, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001; 95% CI: (1.95, 5.84)]. Gray shading indicates 95% confidence intervals. (B) Impact of immunosuppression on diffusion capacity for carbon monoxide (DLCO). There was a significant increase in DLCO % predicted following 12 months of treatment compared to the projected trend without treatment [+4.53%, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span><0.001, (2.12, 6.94)]. <span class="elsevierStyleItalic">Reproduced with permission by Elsevier publishing granted on 2/22/23. Reproduced from CHEST, Matson et al, ISSN: 0012-3692. Copyright Elsevier publishing.</span></p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Scott M. Matson, Joyce S. Lee" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Scott M." "apellidos" => "Matson" ] 1 => array:2 [ "nombre" => "Joyce S." "apellidos" => "Lee" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0121812323000592?idApp=UINPBA00004N" "url" => "/01218123/00000031000000S1/v5_202405200140/S0121812323000592/v5_202405200140/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S0121812323000579" "issn" => "01218123" "doi" => "10.1016/j.rcreu.2023.06.002" "estado" => "S300" "fechaPublicacion" => "2024-04-01" "aid" => "2063" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Rev Colomb Reumatol. 2024;31 Supl 1:S3-S14" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Screening, diagnosis, and monitoring of interstitial lung disease in autoimmune rheumatic diseases: A narrative review" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S3" "paginaFinal" => "S14" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Cribado, diagnóstico y monitoreo de la enfermedad pulmonar intersticial en la enfermedad autoinmune reumática: una revisión narrativa" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1631 "Ancho" => 2925 "Tamanyo" => 268006 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Proposed approach to monitoring for progression of autoimmune-associated ILD within the first 5 years of ILD diagnosis. ILD<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>interstitial lung disease; FVC<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>forced vital capacity; HRCT<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>high resolution computed tomography.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Samuel D. Good, Jeffrey A. Sparks, Elizabeth R. Volkmann" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Samuel D." "apellidos" => "Good" ] 1 => array:2 [ "nombre" => "Jeffrey A." "apellidos" => "Sparks" ] 2 => array:2 [ "nombre" => "Elizabeth R." "apellidos" => "Volkmann" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0121812323000579?idApp=UINPBA00004N" "url" => "/01218123/00000031000000S1/v5_202405200140/S0121812323000579/v5_202405200140/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Systemic sclerosis-associated interstitial lung disease: Diagnostic approaches and challenges" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S15" "paginaFinal" => "S25" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Jessica L. Fairley, Nicole S.L. Goh, Mandana Nikpour" "autores" => array:3 [ 0 => array:3 [ "nombre" => "Jessica L." "apellidos" => "Fairley" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 1 => array:3 [ "nombre" => "Nicole S.L." "apellidos" => "Goh" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 2 => array:4 [ "nombre" => "Mandana" "apellidos" => "Nikpour" "email" => array:1 [ 0 => "m.nikpour@unimelb.edu.au" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Department of Medicine, Faculty of Medicine, Dentistry and Health Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Department of Rheumatology, St. Vincent's Hospital Melbourne, Melbourne, Australia" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Department of Respiratory and Sleep Medicine, Austin Hospital, Melbourne, Australia" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "The Institute for Breathing and Sleep, Melbourne, Australia" "etiqueta" => "d" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Enfermedad pulmonar intersticial asociada a esclerosis sistémica: abordajes y desafíos diagnósticos" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 4341 "Ancho" => 3223 "Tamanyo" => 772869 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">A suggested approach to diagnosis and monitoring of SSc-ILD.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Systemic sclerosis (SSc) is a heterogenous autoimmune disease involving multiple organ systems, characterised by the triad of fibrosis, inflammation and vasculopathy.<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">1</span></a> SSc confers an increased risk of mortality, with a standardised mortality ratio of 2.7–3.4 compared to the general population,<a class="elsevierStyleCrossRefs" href="#bib0600"><span class="elsevierStyleSup">2,3</span></a> and more than 20 years of life lost.<a class="elsevierStyleCrossRef" href="#bib0605"><span class="elsevierStyleSup">3</span></a> Cardiopulmonary complications, particularly interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), are a major contributor to mortality in SSc.<a class="elsevierStyleCrossRef" href="#bib0605"><span class="elsevierStyleSup">3</span></a> SSc-ILD is implicated in 20–35% of SSc-related deaths,<a class="elsevierStyleCrossRefs" href="#bib0600"><span class="elsevierStyleSup">2–4</span></a> and tends to occur early in the disease course, particularly in the first 5 years from symptom onset.<a class="elsevierStyleCrossRefs" href="#bib0615"><span class="elsevierStyleSup">5,6</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">ILD in SSc is highly prevalent, although exact estimates depend on the diagnostic modality used. Up to 75–90% of individuals with SSc will display some abnormality on chest high-resolution computed tomography (HRCT),<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">7,8</span></a> the gold-standard diagnostic investigation for SSc-ILD.<a class="elsevierStyleCrossRef" href="#bib0615"><span class="elsevierStyleSup">5</span></a> While some individuals may have subclinical disease, around 40% will develop moderate or severe disease.<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">9</span></a> Thus, there is a broad spectrum of disease in SSc-ILD, and a variable natural history. Identifying those at highest risk of progressive ILD is important in determining optimal management, as early initiation of treatment to prevent further loss of lung function is likely to improve survival. Here, we aim to summarise current knowledge about SSc-ILD, with emphasis on diagnostic approaches and risk-stratification.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Who is most at risk of ILD in SSc?</span><p id="par0015" class="elsevierStylePara elsevierViewall">Patients with scleroderma at increased risk for developing ILD include those with diffuse cutaneous SSc (dcSSc),<a class="elsevierStyleCrossRefs" href="#bib0620"><span class="elsevierStyleSup">6,10,11</span></a> male sex<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">12</span></a> and anti-Scl-70 antibodies.<a class="elsevierStyleCrossRefs" href="#bib0620"><span class="elsevierStyleSup">6,11,12</span></a> Certain racial groups have also been identified as being at higher risk of developing SSc-ILD, particularly individuals of African-American<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">13</span></a> and Asian<a class="elsevierStyleCrossRefs" href="#bib0660"><span class="elsevierStyleSup">14,15</span></a> ethnicity. People with gastro-oesophageal reflux disease (GORD) also appear to be at higher risk of SSc-ILD.<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">16</span></a> Anti-Scl-70 positivity has been associated with a higher risk of both developing ILD, and more severe ILD on both chest HRCT<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">17</span></a> and as measured by FVC values lower than 70%.<a class="elsevierStyleCrossRefs" href="#bib0640"><span class="elsevierStyleSup">10,17</span></a> Anti-centromere antibody (ACA) positivity confers a lower risk of developing ILD.<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">12</span></a> Data are conflicting regarding ILD risk in those with anti-RNA polymerase-3 (RNAP3) positivity; while some data suggest around 50% of RNAP3-positive individuals may present with ILD,<a class="elsevierStyleCrossRefs" href="#bib0680"><span class="elsevierStyleSup">18,19</span></a> others suggest a lower frequency and less severe ILD in this group.<a class="elsevierStyleCrossRefs" href="#bib0690"><span class="elsevierStyleSup">20,21</span></a> In the two studies reporting 50% ILD prevalence in RNAP3 positive participants, this group tended to have milder disease at baseline.<a class="elsevierStyleCrossRefs" href="#bib0680"><span class="elsevierStyleSup">18,19</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">How should we screen for SSc-ILD?</span><p id="par0020" class="elsevierStylePara elsevierViewall">Screening for ILD is recommended for all patients with SSc and should include assessment of symptoms, chest auscultation, spirometry with DLCO, chest HRCT at baseline, and/or autoantibody testing.<a class="elsevierStyleCrossRef" href="#bib0700"><span class="elsevierStyleSup">22</span></a> The presence of respiratory symptoms, such as exertional dyspnoea and cough, is important in the screening of SSc-ILD, although the use of symptoms alone is unreliable. Respiratory symptoms are often insidious in onset and can be masked by other factors such as relative immobility and pain from musculoskeletal disease. Pulmonary function testing (PFT) remains an important component of screening for, and assessment of, both PAH and ILD in SSc. While FVC is predominantly a marker of the pulmonary interstitium, DLCO is a marker of both the pulmonary interstitium and vasculature. The utility of PFTs is limited by the wide range of normal values. Indeed, up to 60% of individuals with ILD evident on chest HRCT may have normal forced vital capacity (FVC).<a class="elsevierStyleCrossRef" href="#bib0705"><span class="elsevierStyleSup">23</span></a> Chest HRCT remains the gold standard for the detection of ILD and is more sensitive than chest X-ray imaging.<a class="elsevierStyleCrossRefs" href="#bib0615"><span class="elsevierStyleSup">5,23,24</span></a> The radiographic extent of fibrosis at baseline may be associated with FVC decline, with greater than 25% extent of fibrosis on baseline HRCT associated with increased rate of FVC decline.<a class="elsevierStyleCrossRef" href="#bib0715"><span class="elsevierStyleSup">25</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">HRCT staging systems also provide important prognostic information. Radiographic extent of ILD on baseline HRCT is associated with increased mortality, especially with greater than 20% total lung involvement, or 10–20% involvement together with an FVC lower than 70%.<a class="elsevierStyleCrossRefs" href="#bib0720"><span class="elsevierStyleSup">26,27</span></a> Moreover, a normal chest HRCT at baseline confers a lower risk of developing SSc-ILD in future, and thus is associated with a better prognosis.<a class="elsevierStyleCrossRefs" href="#bib0730"><span class="elsevierStyleSup">28,29</span></a> In one study, 85% of people with a normal chest HRCT at baseline did not develop ILD over 5 years.<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">28</span></a> Given that SSc-ILD most commonly develops in the first 5 years of SSc onset, performing chest HRCT around the time of diagnosis seems to be an optimal timepoint.<a class="elsevierStyleCrossRefs" href="#bib0615"><span class="elsevierStyleSup">5,6</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Diagnosis and monitoring of SSc-ILD</span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Imaging studies</span><p id="par0030" class="elsevierStylePara elsevierViewall">Chest HRCT imaging is now considered the gold standard investigation for ILD diagnosis in SSc.<a class="elsevierStyleCrossRefs" href="#bib0615"><span class="elsevierStyleSup">5,23</span></a> The most common radiographic pattern of involvement is non-specific interstitial pneumonia (NSIP), occurring in 70–80% of patients<a class="elsevierStyleCrossRefs" href="#bib0615"><span class="elsevierStyleSup">5,30,31</span></a> (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>), while between 10 and 25% of patients will have a usual interstitial pneumonia (UIP) pattern.<a class="elsevierStyleCrossRefs" href="#bib0740"><span class="elsevierStyleSup">30,31</span></a> NSIP is characterised by the presence of a mixture of reticular and ground glass changes, whereas UIP is characterised by the presence of honeycombing (the cardinal feature) and reticular changes with minimal ground glass opacities.<a class="elsevierStyleCrossRef" href="#bib0750"><span class="elsevierStyleSup">32</span></a> While ground-glass opacities may be an indicator of active inflammatory disease/alveolitis, they can also be a reflection of fine fibrosis, especially if the changes are adjacent to areas of traction bronchiectasis.<a class="elsevierStyleCrossRef" href="#bib0755"><span class="elsevierStyleSup">33</span></a> This is exemplified by the discordance in the frequency of ground glass opacities on CT<a class="elsevierStyleCrossRef" href="#bib0760"><span class="elsevierStyleSup">34</span></a> compared to the frequency of active alveolitis in histopathologic studies in SSc-ILD.<a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">30</span></a></p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">Another benefit of chest HRCT in SSc is the ability to identify other pulmonary pathologies. For example, SSc and SSc-ILD may be associated with an increased risk of lung cancer,<a class="elsevierStyleCrossRef" href="#bib0765"><span class="elsevierStyleSup">35</span></a> which may be identified on chest HRCT imaging, although best assessed on contrast-enhanced standard chest CT imaging. Chest HRCT imaging may identify an enlarged pulmonary artery suggestive of PAH.<a class="elsevierStyleCrossRefs" href="#bib0770"><span class="elsevierStyleSup">36,37</span></a> Furthermore, bronchiectasis may occur more frequently in SSc and is readily detected by chest HRCT.<a class="elsevierStyleCrossRef" href="#bib0780"><span class="elsevierStyleSup">38</span></a> Bronchiectasis appears to occur independently of ILD,<a class="elsevierStyleCrossRef" href="#bib0780"><span class="elsevierStyleSup">38</span></a> suggesting this is a separate pathologic entity which can contribute to dyspnoea, cough and recurrent infections. Additionally, a proportion of individuals may have combined pulmonary fibrosis and emphysema identified on imaging.<a class="elsevierStyleCrossRefs" href="#bib0785"><span class="elsevierStyleSup">39,40</span></a> Emphysematous change can occur in SSc in non-smokers; 62.5% of participants had never smoked in one study of people with SSc with emphysematous change on surgical lung biopsy.<a class="elsevierStyleCrossRef" href="#bib0795"><span class="elsevierStyleSup">41</span></a> Combined emphysema and fibrosis is associated with a lower diffusing capacity for carbon monoxide (DLCO),<a class="elsevierStyleCrossRefs" href="#bib0790"><span class="elsevierStyleSup">40,41</span></a> higher radiographic extent of fibrosis<a class="elsevierStyleCrossRefs" href="#bib0785"><span class="elsevierStyleSup">39,41</span></a> and in one study, small vessel vasculopathy in the pulmonary arteries.<a class="elsevierStyleCrossRef" href="#bib0795"><span class="elsevierStyleSup">41</span></a> It is important to identify this emphysematous change as the consequential reduction in DLCO may confound screening for PAH, and may also contribute to more severe respiratory disease including a higher risk of pulmonary hypertension.<a class="elsevierStyleCrossRef" href="#bib0785"><span class="elsevierStyleSup">39</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">The role of chest HRCT in monitoring progression of SSc-ILD is not yet fully defined. While experts agree that HRCT can be useful in monitoring ILD progression,<a class="elsevierStyleCrossRef" href="#bib0800"><span class="elsevierStyleSup">42</span></a> there is no agreement on how frequently it should be performed. Recent consensus guidelines suggest chest HRCT should be performed according to clinical need, based on the current symptoms, disease state, and the speed of progression.<a class="elsevierStyleCrossRef" href="#bib0800"><span class="elsevierStyleSup">42</span></a> Observational data suggest that most patients with a baseline extent of fibrosis on chest HRCT of <20% continue to remain stable, with a minority (especially those with shorter disease duration) progressing to >20% CT extent.<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">29</span></a> Other data suggest that greater than 25% baseline HRCT extent of fibrosis has been associated with increased FVC decline.<a class="elsevierStyleCrossRef" href="#bib0715"><span class="elsevierStyleSup">25</span></a> Changing HRCT pattern or extent may also be helpful to monitor the impact (or lack thereof) of therapy.<a class="elsevierStyleCrossRef" href="#bib0805"><span class="elsevierStyleSup">43</span></a> Furthermore, changes in HRCT pattern may correlate with other symptom and functional outcomes, with reduced dyspnoea in those with improving quantitative interstitial lung disease scores identified in a subgroup analysis of the Scleroderma Lung Study II.<a class="elsevierStyleCrossRef" href="#bib0810"><span class="elsevierStyleSup">44</span></a> Further data are required to understand the optimal use and timing of serial chest HRCT imaging in SSc-ILD.</p><p id="par0045" class="elsevierStylePara elsevierViewall">Currently, exposure to ionising radiation is a major concern limiting routine repeat use of chest HRCT.<a class="elsevierStyleCrossRef" href="#bib0815"><span class="elsevierStyleSup">45</span></a> Younger age confers increased risk from exposure, with the highest risk in children and young adults.<a class="elsevierStyleCrossRef" href="#bib0820"><span class="elsevierStyleSup">46</span></a> The estimated radiation exposure from chest HRCT scanning is 2–4<span class="elsevierStyleHsp" style=""></span>mSv,<a class="elsevierStyleCrossRef" href="#bib0825"><span class="elsevierStyleSup">47</span></a> compared to standard CT chest imaging of 7<span class="elsevierStyleHsp" style=""></span>mSv<a class="elsevierStyleCrossRef" href="#bib0830"><span class="elsevierStyleSup">48</span></a> or low-dose lung cancer CT screening of 1.4<span class="elsevierStyleHsp" style=""></span>mSv.<a class="elsevierStyleCrossRef" href="#bib0835"><span class="elsevierStyleSup">49</span></a> For broader context, annual background radiation exposure worldwide is estimated to be 2.4<span class="elsevierStyleHsp" style=""></span>mSv per annum,<a class="elsevierStyleCrossRef" href="#bib0840"><span class="elsevierStyleSup">50</span></a> and the World Health Organisation suggests a threshold lifetime exposure potentially associated with increased cancer risk of 100<span class="elsevierStyleHsp" style=""></span>mSv.<a class="elsevierStyleCrossRef" href="#bib0820"><span class="elsevierStyleSup">46</span></a> Recent technological advances may allow lower-dose CT protocols to be used in ILD monitoring.<a class="elsevierStyleCrossRefs" href="#bib0815"><span class="elsevierStyleSup">45,51</span></a> Low-dose and ultra-low dose CT imaging techniques have been used in other contexts, for example lung cancer screening<a class="elsevierStyleCrossRef" href="#bib0850"><span class="elsevierStyleSup">52</span></a> and monitoring of pulmonary nodules,<a class="elsevierStyleCrossRef" href="#bib0855"><span class="elsevierStyleSup">53</span></a> although these have been more difficult to apply in ILD. Advanced image reconstruction methods, including iterative reconstruction techniques, use of limited axial scans (using thin slices over large intervals e.g., every 10–20<span class="elsevierStyleHsp" style=""></span>mm), using detector systems with increased efficacy and automatic exposure control are all strategies to reduce radiation exposure.<a class="elsevierStyleCrossRef" href="#bib0815"><span class="elsevierStyleSup">45</span></a> Lower dose chest HRCT scanning is likely to be a valuable tool in SSc-ILD, particularly in monitoring after an initial diagnosis.</p><p id="par0050" class="elsevierStylePara elsevierViewall">No other imaging investigation is currently routinely recommended in clinical practice for diagnosis, screening or monitoring of SSc-ILD. However, much interest in other modalities has arisen in an attempt to minimise radiation exposure, particularly in monitoring SSc-ILD where serial testing may be required. Ultrasound imaging of the lung may be able to identify features suspicious for ILD.<a class="elsevierStyleCrossRef" href="#bib0815"><span class="elsevierStyleSup">45</span></a> In particular, ultrasound detection of multiple “B-lines”, pleural irregularity and pleural thickening can predict HRCT diagnosis of SSc-ILD.<a class="elsevierStyleCrossRefs" href="#bib0860"><span class="elsevierStyleSup">54,55</span></a> Magnetic resonance imaging (MRI) may give some information about inflammatory changes in the lung in pulmonary fibrosis.<a class="elsevierStyleCrossRefs" href="#bib0870"><span class="elsevierStyleSup">56,57</span></a> However, chest HRCT currently provides superior imaging quality compared to lung MRI.<a class="elsevierStyleCrossRef" href="#bib0815"><span class="elsevierStyleSup">45</span></a> Positron emission tomography combined with CT (PET-CT) may identify increased <span class="elsevierStyleSup">18F</span>FDG (Fluorodeoxyglucose F18) uptake within the lungs in myositis-associated ILD, which may help both in diagnosis and to identify those at risk of rapidly progressive ILD.<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">58</span></a> Further data are required in SSc cohorts to identify the role of these imaging modalities in SSc-ILD in both diagnosis and monitoring, especially where ionising radiation exposure may be lessened or avoided.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Pulmonary function testing</span><p id="par0055" class="elsevierStylePara elsevierViewall">While limitations exist when PFT are used in isolation as a screening or diagnostic test for ILD, they remain important in monitoring of SSc-ILD (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). This is particularly true given the exposure to ionising radiation with serial HRCT examinations. PFT convey important prognostic information and are important in assessing ILD severity and defining clinically significant disease.<a class="elsevierStyleCrossRef" href="#bib0800"><span class="elsevierStyleSup">42</span></a> It is recommended that PFT are repeated every 3–6 months in those with ILD, with more frequent testing earlier in the disease course where risk of progression is highest<a class="elsevierStyleCrossRef" href="#bib0885"><span class="elsevierStyleSup">59</span></a> (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). In those without ILD, PFT can be monitored annually to screen for both ILD and PAH.</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0060" class="elsevierStylePara elsevierViewall">Small declines in FVC and DLCO are associated with reduced survival.<a class="elsevierStyleCrossRefs" href="#bib0885"><span class="elsevierStyleSup">59–61</span></a> The estimated clinically important difference for percent-predicted FVC is only 2–6%, with an estimated test–retest variability of PFT measurements of around 5–10%.<a class="elsevierStyleCrossRefs" href="#bib0885"><span class="elsevierStyleSup">59,62</span></a> Risk of progression is highest in the first 4–5 years of ILD, where close monitoring is recommended.<a class="elsevierStyleCrossRef" href="#bib0885"><span class="elsevierStyleSup">59</span></a> In one study, those who maintain stable PFT for around 4 years post-ILD diagnosis were at lowest risk of ILD progression.<a class="elsevierStyleCrossRef" href="#bib0885"><span class="elsevierStyleSup">59</span></a> However, stability of FVC over one time interval does not guarantee future stability. Up to 30% of individuals with a previously stable FVC may experience significant deterioration in the subsequent 12 months,<a class="elsevierStyleCrossRef" href="#bib0905"><span class="elsevierStyleSup">63</span></a> highlighting the need for serial PFT monitoring.</p><p id="par0065" class="elsevierStylePara elsevierViewall">PFT in SSc provide important additional benefits, particularly in screening for pulmonary hypertension. The development of pulmonary hypertension, including precapillary PAH, has major prognostic and functional implications in SSc and can develop in those with SSc-ILD.<a class="elsevierStyleCrossRefs" href="#bib0665"><span class="elsevierStyleSup">15,29,64</span></a> PFT are a useful tool in screening for SSc-PH, particularly if DLCO declines out of proportion to change in FVC. Early identification of PAH is critically important and improves survival and haemodynamics.<a class="elsevierStyleCrossRefs" href="#bib0915"><span class="elsevierStyleSup">65–67</span></a> PFT results may help to identify anaemia where haemoglobin testing is performed to assess oxygen transfer, as well as extra-thoracic restriction related to severe skin involvement. Furthermore, PFT can also assess for respiratory muscle weakness in those with SSc and myositis overlap syndromes.<a class="elsevierStyleCrossRef" href="#bib0930"><span class="elsevierStyleSup">68</span></a> Accordingly, PFT continue to have an important role in monitoring SSc-ILD, assisting with prognostication, and in detecting other SSc complications or contributors to breathlessness.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Six-minute walk testing</span><p id="par0070" class="elsevierStylePara elsevierViewall">Serial six-minute walk testing (6MWT) may also be a helpful tool in monitoring individuals with SSc-ILD and PAH, with the combined utility of measuring both distance walked and detecting exertional desaturation using oxygen saturation on room air and with supplemental oxygen where appropriate.<a class="elsevierStyleCrossRef" href="#bib0935"><span class="elsevierStyleSup">69</span></a> 6MWTs can help to monitor functional exercise capacity in a standardised way, although the results can be affected by non-cardiopulmonary contributors to exercise intolerance (e.g., joint or muscle pathology) in SSc.<a class="elsevierStyleCrossRef" href="#bib0935"><span class="elsevierStyleSup">69</span></a> Those with SSc-PAH may have shorter six-minute walk distances than those with SSc-ILD alone.<a class="elsevierStyleCrossRef" href="#bib0935"><span class="elsevierStyleSup">69</span></a> However, the utility of 6MWT in monitoring SSc-ILD is unknown. In a meta-analysis of randomised controlled trial data in non-SSc cohorts with PAH, change in 6MWD measurements did not correlate with clinical outcomes (death, hospitalisation, or rescue PAH therapy).<a class="elsevierStyleCrossRef" href="#bib0940"><span class="elsevierStyleSup">70</span></a></p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Invasive investigations</span><p id="par0075" class="elsevierStylePara elsevierViewall">Previously, surgical lung biopsy was commonly performed to investigate SSc-ILD and define the pattern of involvement.<a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">30</span></a> However, this has been largely superseded by HRCT imaging as a reliable and non-invasive tool to determine ILD subtype, unless exclusion of malignancy or an alternate pathology is required.<a class="elsevierStyleCrossRef" href="#bib0945"><span class="elsevierStyleSup">71</span></a> Bronchoscopy and bronchoalveolar lavage (BAL) can be used both to exclude infection, and to guide prognosis and treatment in ILD. Higher neutrophil count on bronchoalveolar lavage has been shown to correlate with more extensive disease on CT, and more fibrotic disease.<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">72</span></a> Inflammatory BAL results suggestive of alveolitis are associated with more severe restrictive ventilatory defects.<a class="elsevierStyleCrossRefs" href="#bib0955"><span class="elsevierStyleSup">73,74</span></a> However, the invasive nature of bronchoscopy and variable analytical techniques in processing of BAL samples has limited its widespread use.<a class="elsevierStyleCrossRef" href="#bib0960"><span class="elsevierStyleSup">74</span></a> Furthermore, whether BAL results confer additional prognostic or therapeutic information beyond non-invasive testing is uncertain.<a class="elsevierStyleCrossRef" href="#bib0960"><span class="elsevierStyleSup">74</span></a> It is possible that with the advent of novel biomarkers for SSc-ILD, analysis of specific biomarkers on BAL sampling may be beneficial in risk-stratification or determining the likelihood of treatment success.<a class="elsevierStyleCrossRefs" href="#bib0945"><span class="elsevierStyleSup">71,74</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Multidisciplinary team discussion in SSc-ILD diagnosis and management</span><p id="par0080" class="elsevierStylePara elsevierViewall">Multidisciplinary team (MDT) discussions play an important role in diagnosis<a class="elsevierStyleCrossRefs" href="#bib0965"><span class="elsevierStyleSup">75,76</span></a> and management of ILD.<a class="elsevierStyleCrossRef" href="#bib0975"><span class="elsevierStyleSup">77</span></a> Whilst the diagnosis of ILD in the presence of confirmed SSc is usually clear, identifying disease progression and deciding when to adjust treatment can be more difficult. Furthermore, the clinical features of SSc can be subtle in a patient with de novo ILD. Consideration should be given to discussing those with SSc-ILD at a multidisciplinary meeting which includes the treating rheumatologist, along with a radiologist and respiratory physician. Studies suggest including the rheumatologist in this multidisciplinary meeting is beneficial; in one review, only 24% of general ILD multidisciplinary meetings included a rheumatologist.<a class="elsevierStyleCrossRef" href="#bib0975"><span class="elsevierStyleSup">77</span></a> However, ILD multidisciplinary meetings have an important role in adjusting immunosuppression and increasing use of non-corticosteroid immunosuppression in ILD, particularly connective tissue disease (CTD)-associated ILD.<a class="elsevierStyleCrossRef" href="#bib0980"><span class="elsevierStyleSup">78</span></a> Inclusion of a rheumatologist in multidisciplinary discussions has been shown to assist with modifying treatment in up to 80% of CTD-ILD cases.<a class="elsevierStyleCrossRefs" href="#bib0975"><span class="elsevierStyleSup">77,79</span></a></p></span></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Defining ILD progression</span><p id="par0085" class="elsevierStylePara elsevierViewall">Not all individuals with chest HRCT abnormalities develop progressive ILD, thus it is important that all patients with SSc-ILD are closely monitored, particularly early in the disease course. Monitoring for ILD progression should include regular assessment of symptoms and exercise tolerance, physical examination, and pulmonary function tests.<a class="elsevierStyleCrossRef" href="#bib0990"><span class="elsevierStyleSup">80</span></a> While there are no current recommendations about the indications for, and timing of, serial chest HRCT examination, this may be considered in the case of progressive symptoms, to assess treatment response, and to investigate acute exacerbations.</p><p id="par0090" class="elsevierStylePara elsevierViewall">There is no current universally accepted definition for SSc-ILD progression.<a class="elsevierStyleCrossRefs" href="#bib0995"><span class="elsevierStyleSup">81–83</span></a> However, the OMERACT CTD-ILD working group have proposed the following definition for clinically-meaningful progression in CTD-ILD, now widely accepted in SSc<a class="elsevierStyleCrossRefs" href="#bib0990"><span class="elsevierStyleSup">80,83</span></a>; ≥10% relative decline in FVC (%) or ≥5 to –<10% relative decline in FVC (%) and ≥15% relative decline in DLCO (%).<a class="elsevierStyleCrossRef" href="#bib1010"><span class="elsevierStyleSup">84</span></a> This definition is generally applied over 1–2 years.<a class="elsevierStyleCrossRef" href="#bib0990"><span class="elsevierStyleSup">80</span></a> Radiographic progression is also an important indicator, where these data are available, although the minimum clinically important change in HRCT extent is yet to be defined. Some data suggest that early radiographic progression in SSc-ILD may be associated with worse survival. In a subgroup analysis of Scleroderma Lung Study I and II participants, ≥2% progression on chest HRCT using quantitative imaging analysis was associated with worse survival.<a class="elsevierStyleCrossRef" href="#bib1015"><span class="elsevierStyleSup">85</span></a> Further data are required to optimally define SSc-ILD progression, and in particular radiographic progression on HRCT.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Can we predict who will develop progressive SSc-ILD?</span><p id="par0095" class="elsevierStylePara elsevierViewall">Predicting who will develop progressive ILD is critically important in optimising both the intensity of monitoring and treatment. While much work has been done to identify features associated with higher risk of ILD progression, this remains an imprecise science. Older age at SSc onset,<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">12</span></a> dcSSc<a class="elsevierStyleCrossRefs" href="#bib0905"><span class="elsevierStyleSup">63,86</span></a> and male sex<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">12</span></a> have both been associated with increased risk of ILD progression. People with ACA positivity are likely to be at lower risk of ILD progression<a class="elsevierStyleCrossRefs" href="#bib0730"><span class="elsevierStyleSup">28,29</span></a>; ACA positivity has been associated with milder ILD<a class="elsevierStyleCrossRef" href="#bib0890"><span class="elsevierStyleSup">60</span></a> and preservation of lung function.<a class="elsevierStyleCrossRefs" href="#bib0735"><span class="elsevierStyleSup">29,87</span></a> Although anti-Scl-70 positivity is associated with the development of ILD,<a class="elsevierStyleCrossRefs" href="#bib0620"><span class="elsevierStyleSup">6,11,12</span></a> its utility as a marker of progression is unclear. While some data suggest anti-Scl-70 positivity may be associated with ILD progression,<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">12,88</span></a> other data have failed to identify an association between anti-Scl-70 positivity and either radiographic progression or an FVC decline of greater than 10%.<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">17</span></a> Data are conflicting regarding RNAP3 positivity and ILD progression. In one study assessing radiographic progression of RNAP3 positive participants on HRCT, only 18% developed severe fibrosis after 3 years.<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">19</span></a> In contrast, a greater proportion of participants with RNAP3 positivity progressed compared to those with anti-Scl-70 positivity.<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">19</span></a> Gastroesophageal reflux disease (GORD) has also been identified as an important contributor to SSc-ILD progression.<a class="elsevierStyleCrossRefs" href="#bib1035"><span class="elsevierStyleSup">89,90</span></a> In one study the burden of reflux symptoms was associated with greater progression of SSc-ILD.<a class="elsevierStyleCrossRef" href="#bib1035"><span class="elsevierStyleSup">89</span></a> This underscores the importance of aggressive anti-reflux treatment in those with SSc-ILD.</p><p id="par0100" class="elsevierStylePara elsevierViewall">Markers of increased ILD severity at baseline have been shown to confer increased risk of progression. These include higher baseline radiographic extent of fibrosis,<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">12,27,29</span></a> particularly greater than 20% extent of fibrosis on HRCT chest,<a class="elsevierStyleCrossRefs" href="#bib0725"><span class="elsevierStyleSup">27,29</span></a> reduced FVC levels,<a class="elsevierStyleCrossRefs" href="#bib0620"><span class="elsevierStyleSup">6,12</span></a> reduced DLCO levels<a class="elsevierStyleCrossRefs" href="#bib0620"><span class="elsevierStyleSup">6,12</span></a> and decreased oxygen saturation.<a class="elsevierStyleCrossRefs" href="#bib1025"><span class="elsevierStyleSup">87,91</span></a> Outcomes appear to be more closely linked to ILD severity at presentation and decline in PFT parameters rather than baseline HRCT pattern.<a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">30</span></a></p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Other tools in SSc-ILD: the promise of biomarkers in ILD diagnosis and risk stratification</span><p id="par0105" class="elsevierStylePara elsevierViewall">While not yet routinely used in clinical practice, novel biomarkers detected in both serum and bronchoalveolar lavage fluid have been shown to be associated with both the presence and progression of SSc-ILD.<a class="elsevierStyleCrossRef" href="#bib1050"><span class="elsevierStyleSup">92</span></a> CC chemokine ligane-18 (CCL-18) is a chemokine expressed by alveolar macrophages, while carbohydrate antigen 15.3 (CA15-3) and Krebs von Lungen-6 (KL-6) are both glycoproteins encoded by the gene MUC1.<a class="elsevierStyleCrossRef" href="#bib1055"><span class="elsevierStyleSup">93</span></a> Interleukin-6 (IL-6) is a proinflammatory cytokine.<a class="elsevierStyleCrossRef" href="#bib1060"><span class="elsevierStyleSup">94</span></a> Ca15-3,<a class="elsevierStyleCrossRef" href="#bib1065"><span class="elsevierStyleSup">95</span></a> KL-6,<a class="elsevierStyleCrossRef" href="#bib1050"><span class="elsevierStyleSup">92</span></a> IL-8,<a class="elsevierStyleCrossRef" href="#bib1050"><span class="elsevierStyleSup">92</span></a> IL-6<a class="elsevierStyleCrossRef" href="#bib1070"><span class="elsevierStyleSup">96</span></a> and surfactant protein D<a class="elsevierStyleCrossRef" href="#bib1050"><span class="elsevierStyleSup">92</span></a> may all be associated with the presence of ILD, while CCL-18<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">12,97,98</span></a> and Ca15-3<a class="elsevierStyleCrossRef" href="#bib1085"><span class="elsevierStyleSup">99</span></a> may be associated with increased ILD severity. CA15-3 may also correlate with dyspnoea.<a class="elsevierStyleCrossRef" href="#bib1085"><span class="elsevierStyleSup">99</span></a> CCL-18<a class="elsevierStyleCrossRefs" href="#bib1075"><span class="elsevierStyleSup">97,98</span></a> and CCL-2<a class="elsevierStyleCrossRefs" href="#bib1090"><span class="elsevierStyleSup">100,101</span></a> levels may be associated with survival, while KL-6 has also been associated with survival in cohorts with idiopathic pulmonary fibrosis.<a class="elsevierStyleCrossRef" href="#bib1100"><span class="elsevierStyleSup">102</span></a> CCL-2,<a class="elsevierStyleCrossRef" href="#bib1095"><span class="elsevierStyleSup">101</span></a> Ca15-3<a class="elsevierStyleCrossRef" href="#bib1105"><span class="elsevierStyleSup">103</span></a> and KL-6<a class="elsevierStyleCrossRefs" href="#bib0675"><span class="elsevierStyleSup">17,104</span></a> are associated with greater radiographic extent of ILD, while CCL-18,<a class="elsevierStyleCrossRefs" href="#bib0675"><span class="elsevierStyleSup">17,97,98,105</span></a> CCL-2,<a class="elsevierStyleCrossRefs" href="#bib1090"><span class="elsevierStyleSup">100,101</span></a> Ca15-3,<a class="elsevierStyleCrossRefs" href="#bib1085"><span class="elsevierStyleSup">99,106</span></a> KL-6<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">12,107,108</span></a> and surfactant protein D<a class="elsevierStyleCrossRefs" href="#bib0675"><span class="elsevierStyleSup">17,105,109,110</span></a> may correlate with PFT measurements. CCL-2,<a class="elsevierStyleCrossRefs" href="#bib1090"><span class="elsevierStyleSup">100,101</span></a> Ca15-3<a class="elsevierStyleCrossRefs" href="#bib1085"><span class="elsevierStyleSup">99,106</span></a> and KL-6<a class="elsevierStyleCrossRefs" href="#bib1125"><span class="elsevierStyleSup">107,111</span></a> may be associated with ILD progression or PFT decline; data are conflicting about the role of IL-6 in progression.<a class="elsevierStyleCrossRefs" href="#bib1090"><span class="elsevierStyleSup">100,112</span></a> In one study, the use of a composite score including surfactant protein D, Ca15-3 and Intercellular Adhesion Molecule 1 (ICAM-1) was found to be more predictive of disease than individual markers alone.<a class="elsevierStyleCrossRef" href="#bib1155"><span class="elsevierStyleSup">113</span></a> The utility of this composite score as a prognostic marker is currently unknown. Multiple other biomarkers are currently under investigation, and all need to be validated in large, multicentre, prospective studies involving different racial groups.<a class="elsevierStyleCrossRef" href="#bib1160"><span class="elsevierStyleSup">114</span></a></p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Other contributors to respiratory symptoms in SSc-ILD</span><p id="par0110" class="elsevierStylePara elsevierViewall">Dyspnoea is an important symptom of SSc-ILD, and an increase in dyspnoea is generally associated with progressive disease. However, several co-morbidities in SSc may also to contribute to this symptomology. Co-existing pulmonary hypertension is not uncommon in SSc-ILD and should be considered if there is a disproportionate drop in DLCO levels in relation to FVC levels. Data from the Australian Scleroderma Cohort study (ASCS), a large multicentre prospective cohort study of SSc, demonstrated that of 479 people with ILD, 106 (22.1%) also fulfilled RHC criteria for PAH.<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">15</span></a> People with ILD combined with PAH have significantly worse physical function and survival compared to those with ILD alone.<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">15</span></a> Concurrent left heart disease is common in SSc and left ventricular diastolic dysfunction (LVDD) occurs in 20–30% of people with SSc.<a class="elsevierStyleCrossRefs" href="#bib1165"><span class="elsevierStyleSup">115–117</span></a> Finally, anaemia and iron deficiency, skeletal muscle disease and respiratory muscle weakness, and fatigue can all contribute to reduced exercise tolerance and dyspnoea in people with SSc. Moreover, cough in SSc may also be multifactorial; post hoc analyses of the SSc Lung Study II data demonstrated that frequent cough was associated with more GORD symptoms.<a class="elsevierStyleCrossRef" href="#bib1180"><span class="elsevierStyleSup">118</span></a> Accordingly, it is important to optimise anti-reflux treatment in anyone with SSc-ILD to avoid ILD progression,<a class="elsevierStyleCrossRef" href="#bib1035"><span class="elsevierStyleSup">89</span></a> but also to optimise health-related quality of life and reduce symptom burden. A holistic approach and consideration of differential diagnoses is important in assessment of worsening respiratory symptoms in people with SSc-ILD.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Conclusions</span><p id="par0115" class="elsevierStylePara elsevierViewall">ILD is an important contributor to morbidity and mortality in SSc. There are well characterised clinical and serological factors that confer both an increased risk of ILD development and progression of ILD. Screening for ILD in SSc is recommended in all patients at baseline, and HRCT chest imaging is pivotal in the diagnosis of SSc-ILD. However, the role of chest HRCT in routine monitoring of SSc-ILD is yet to be established. PFTs remain the mainstay of ILD monitoring and should be performed every 3–6 months; more frequently during the first 5 years of disease where patients are at the highest risk of disease progression. Advances in novel biomarker discovery and other imaging modalities are likely to improve risk stratification and clinical care in SSc-ILD.</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Conflict of interest</span><p id="par0120" class="elsevierStylePara elsevierViewall">JF has received conference sponsorship from Pfizer and honoraria from Boehringer-Ingelheim. MN has received honoraria or consultancies from Janssen, AstraZeneca, GlaxoSmithKlein, Boehringer-Ingelheim and Bristol-Myers Squibb. NG has received honoraria or consultancies from Boehringer-Ingelheim and Astra Zeneca, and an equipment grant from Air Liquide.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:16 [ 0 => array:3 [ "identificador" => "xres2149706" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1824863" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres2149705" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1824864" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Who is most at risk of ILD in SSc?" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "How should we screen for SSc-ILD?" ] 7 => array:3 [ "identificador" => "sec0020" "titulo" => "Diagnosis and monitoring of SSc-ILD" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0025" "titulo" => "Imaging studies" ] 1 => array:2 [ "identificador" => "sec0030" "titulo" => "Pulmonary function testing" ] 2 => array:2 [ "identificador" => "sec0035" "titulo" => "Six-minute walk testing" ] 3 => array:2 [ "identificador" => "sec0040" "titulo" => "Invasive investigations" ] 4 => array:2 [ "identificador" => "sec0045" "titulo" => "Multidisciplinary team discussion in SSc-ILD diagnosis and management" ] ] ] 8 => array:2 [ "identificador" => "sec0050" "titulo" => "Defining ILD progression" ] 9 => array:2 [ "identificador" => "sec0055" "titulo" => "Can we predict who will develop progressive SSc-ILD?" ] 10 => array:2 [ "identificador" => "sec0060" "titulo" => "Other tools in SSc-ILD: the promise of biomarkers in ILD diagnosis and risk stratification" ] 11 => array:2 [ "identificador" => "sec0065" "titulo" => "Other contributors to respiratory symptoms in SSc-ILD" ] 12 => array:2 [ "identificador" => "sec0070" "titulo" => "Conclusions" ] 13 => array:2 [ "identificador" => "sec0075" "titulo" => "Conflict of interest" ] 14 => array:2 [ "identificador" => "xack745971" "titulo" => "Acknowledgements" ] 15 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2023-05-31" "fechaAceptado" => "2023-07-07" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1824863" "palabras" => array:4 [ 0 => "Systemic sclerosis" 1 => "Interstitial lung disease" 2 => "Screening" 3 => "Diagnosis" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1824864" "palabras" => array:4 [ 0 => "Esclerosis sistémica" 1 => "Enfermedad pulmonar intersticial" 2 => "Cribado" 3 => "Diagnóstico" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Interstitial lung disease (ILD) is a leading cause of both morbidity and mortality in systemic sclerosis (SSc). Radiographic lung abnormalities on high-resolution computed tomography (HRCT) imaging may be identified in 75–90% of those with SSc, while clinically significant ILD occurs in up to 40%. Early detection is important as early treatment in those with progressive ILD may improve outcomes. Appropriately risk-stratifying systemic sclerosis-associated ILD (SSc-ILD) is important in identifying those at highest risk of progression. This article summarises recent advances in SSc-ILD, particularly recommendations for screening, defining disease progression and monitoring.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">La enfermedad pulmonar intersticial (EPI) es una de las principales causas de morbimortalidad en la esclerosis sistémica (SSc). Las anomalías pulmonares radiográficas en la tomografía computarizada de alta resolución pueden identificarse en el 75-90% de las personas con SSc, mientras que la EPI clínicamente significativa ocurre hasta en el 40%. La detección temprana es importante, ya que el tratamiento oportuno de los pacientes con EPI progresiva puede mejorar los resultados. Es importante estratificar adecuadamente el riesgo de EPI asociada a la esclerosis sistémica (SSc-EPI) para identificar a las personas con mayor riesgo de progresión. Este artículo resume los avances recientes en SSc-EPI, en particular las recomendaciones para la detección, la definición de la progresión de la enfermedad y el seguimiento.</p></span>" ] ] "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "<p id="par0195" class="elsevierStylePara elsevierViewall">The following are the supplementary material to this article:<elsevierMultimedia ident="upi0005"></elsevierMultimedia></p>" "etiqueta" => "Appendix A" "titulo" => "Supplementary material" "identificador" => "sec0085" ] ] ] ] "multimedia" => array:3 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 994 "Ancho" => 1674 "Tamanyo" => 219465 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Chest HRCT features in SSc-ILD. Arrows indicate different radiographic features. (1) Ground glass opacification, (2) traction bronchiectasis, (3) subpleural sparing, and (4) lung nodule.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 4341 "Ancho" => 3223 "Tamanyo" => 772869 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">A suggested approach to diagnosis and monitoring of SSc-ILD.</p>" ] ] 2 => array:5 [ "identificador" => "upi0005" "tipo" => "MULTIMEDIAECOMPONENTE" "mostrarFloat" => false "mostrarDisplay" => true "Ecomponente" => array:2 [ "fichero" => "mmc1.pdf" "ficheroTamanyo" => 466313 ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:118 [ 0 => array:3 [ "identificador" => "bib0595" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nrrheum.2011.149" "Revista" => array:6 [ "tituloSerie" => "Nat Rev Rheumatol" "fecha" => "2011" "volumen" => "8" "paginaInicial" => "42" "paginaFinal" => "54" "link" => array:1 [ …1] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0600" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mortality and survival in systemic sclerosis: systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2014.05.010" "Revista" => array:6 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "2014" "volumen" => "44" "paginaInicial" => "208" "paginaFinal" => "219" "link" => array:1 [ …1] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0605" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early mortality in a multinational systemic sclerosis inception cohort" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.40027" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheumatol" "fecha" => "2017" "volumen" => "69" "paginaInicial" => "1067" "paginaFinal" => "1077" "link" => array:1 [ …1] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0610" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2009.114264" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2010" "volumen" => "69" "paginaInicial" => "1809" "paginaFinal" => "1815" "link" => array:1 [ …1] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0615" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(17)30933-9" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2017" "volumen" => "390" "paginaInicial" => "1685" "paginaFinal" => "1699" "link" => array:1 [ …1] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0620" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prediction of pulmonary complications and long-term survival in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.38390" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheumatol" "fecha" => "2014" "volumen" => "66" "paginaInicial" => "1625" "paginaFinal" => "1635" "link" => array:1 [ …1] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0625" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1148/radiology.176.3.2389033" "Revista" => array:6 [ "tituloSerie" => "Radiology" "fecha" => "1990" "volumen" => "176" "paginaInicial" => "755" "paginaFinal" => "759" "link" => array:1 [ …1] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0630" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interstitial lung disease in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.autrev.2010.09.012" "Revista" => array:6 [ "tituloSerie" => "Autoimmun Rev" "fecha" => "2011" "volumen" => "10" "paginaInicial" => "248" "paginaFinal" => "255" "link" => array:1 [ …1] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0635" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Severe restrictive lung disease in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.1780370903" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "1994" "volumen" => "37" "paginaInicial" => "1283" "paginaFinal" => "1289" "link" => array:1 [ …1] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0640" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interstitial lung disease in systemic sclerosis: data from the Spanish scleroderma study group" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00296-017-3916-x" "Revista" => array:6 [ "tituloSerie" => "Rheumatol Int" "fecha" => "2018" "volumen" => "38" "paginaInicial" => "363" "paginaFinal" => "374" "link" => array:1 [ …1] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0645" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Disease-related autoantibody profile in patients with systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/08916934.2017.1357699" "Revista" => array:6 [ "tituloSerie" => "Autoimmunity" "fecha" => "2017" "volumen" => "50" "paginaInicial" => "414" "paginaFinal" => "421" "link" => array:1 [ …1] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0650" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201903-0563CI" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2020" "volumen" => "201" "paginaInicial" => "650" "paginaFinal" => "660" "link" => array:1 [ …1] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0655" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.34482" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2012" "volumen" => "64" "paginaInicial" => "2986" "paginaFinal" => "2994" "link" => array:1 [ …1] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0660" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Increased mortality in Asians with systemic sclerosis in Northern California" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/acr2.11126" "Revista" => array:6 [ "tituloSerie" => "ACR Open Rheumatol" "fecha" => "2020" "volumen" => "2" "paginaInicial" => "197" "paginaFinal" => "206" "link" => array:1 [ …1] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0665" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical characteristics and survival of combined pulmonary arterial hypertension and interstitial lung disease in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s13075-023-03059-x" "Revista" => array:2 [ "tituloSerie" => "Arthritis Res Ther" "fecha" => "2023" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0670" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2010.03.002" "Revista" => array:6 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "2010" "volumen" => "40" "paginaInicial" => "241" "paginaFinal" => "249" "link" => array:1 [ …1] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0675" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.40815" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheumatol" "fecha" => "2019" "volumen" => "71" "paginaInicial" => "972" "paginaFinal" => "982" "link" => array:1 [ …1] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0680" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.101144" "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2011" "volumen" => "38" "paginaInicial" => "1329" "paginaFinal" => "1334" "link" => array:1 [ …1] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0685" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiopulmonary disease development in anti-RNA polymerase III-positive systemic sclerosis: comparative analyses from an unselected, prospective patient cohort" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.160867" "Revista" => array:7 [ "tituloSerie" => "J Rheumatol" "fecha" => "2017" "volumen" => "44" "paginaInicial" => "459" "paginaFinal" => "465" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0690" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2007.08392.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2008" "volumen" => "158" "paginaInicial" => "487" "paginaFinal" => "495" "link" => array:1 [ …1] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0695" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Autoantibodies in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2005.03.005" "Revista" => array:6 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "2005" "volumen" => "35" "paginaInicial" => "35" "paginaFinal" => "42" "link" => array:1 [ …1] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0700" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Expert consensus on the management of systemic sclerosis-associated interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s12931-022-02292-3" "Revista" => array:3 [ "tituloSerie" => "Respir Res" "fecha" => "2023" "volumen" => "24" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0705" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.39405" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheumatol" "fecha" => "2015" "volumen" => "67" "paginaInicial" => "3256" "paginaFinal" => "3261" "link" => array:1 [ …1] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0710" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1148/radiology.171.1.2928513" "Revista" => array:6 [ "tituloSerie" => "Radiology" "fecha" => "1989" "volumen" => "171" "paginaInicial" => "111" "paginaFinal" => "116" "link" => array:1 [ …1] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0715" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.30467" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2011" "volumen" => "63" "paginaInicial" => "3078" "paginaFinal" => "3085" "link" => array:1 [ …1] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0720" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/kes289" "Revista" => array:6 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2013" "volumen" => "52" "paginaInicial" => "155" "paginaFinal" => "160" "link" => array:1 [ …1] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0725" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interstitial lung disease in systemic sclerosis: a simple staging system" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200706-877OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2008" "volumen" => "177" "paginaInicial" => "1248" "paginaFinal" => "1254" "link" => array:1 [ …1] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0730" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2006" "volumen" => "33" "paginaInicial" => "1789" "paginaFinal" => "1801" "link" => array:1 [ …1] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0735" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.39166" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheumatol" "fecha" => "2015" "volumen" => "67" "paginaInicial" => "2205" "paginaFinal" => "2212" "link" => array:1 [ …1] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0740" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.2106012" "Revista" => array:7 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2002" "volumen" => "165" "paginaInicial" => "1581" "paginaFinal" => "1586" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0745" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "HRCT imaging features of systemic sclerosis-associated interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.29328/journal.jro.1001036" "Revista" => array:5 [ "tituloSerie" => "J Radiol Oncol" "fecha" => "2021" "volumen" => "5" "paginaInicial" => "35" "paginaFinal" => "41" ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0750" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cyclophosphamide versus placebo in scleroderma lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa055120" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2006" "volumen" => "354" "paginaInicial" => "2655" "paginaFinal" => "2666" "link" => array:1 [ …1] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0755" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-resolution computed tomography and scleroderma lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/ken271" "Revista" => array:7 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2008" "volumen" => "47" "numero" => "Suppl. 5" "paginaInicial" => "v59" "paginaFinal" => "v61" "link" => array:1 [ …1] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0760" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1148/radiol.2322031223" "Revista" => array:6 [ "tituloSerie" => "Radiology" "fecha" => "2004" "volumen" => "232" "paginaInicial" => "560" "paginaFinal" => "567" "link" => array:1 [ …1] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0765" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incidence, risk factors, and outcomes of cancer in systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/acr.24076" "Revista" => array:6 [ "tituloSerie" => "Arthritis Care Res (Hoboken)" "fecha" => "2020" "volumen" => "72" "paginaInicial" => "1625" "paginaFinal" => "1635" "link" => array:1 [ …1] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0770" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "CT findings in diseases associated with pulmonary hypertension: a current review" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1148/rg.307105710" "Revista" => array:6 [ "tituloSerie" => "Radiographics" "fecha" => "2010" "volumen" => "30" "paginaInicial" => "1753" "paginaFinal" => "1777" "link" => array:1 [ …1] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0775" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reference values for normal pulmonary artery dimensions by noncontrast cardiac computed tomography: the Framingham Heart Study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/CIRCIMAGING.111.968610" "Revista" => array:6 [ "tituloSerie" => "Circ Cardiovasc Imaging" "fecha" => "2012" "volumen" => "5" "paginaInicial" => "147" "paginaFinal" => "154" "link" => array:1 [ …1] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0780" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The emerging association between bronchiectasis and systemic sclerosis: assessing prevalence and potential causality" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/imj.15661" "Revista" => array:6 [ "tituloSerie" => "Intern Med J" "fecha" => "2023" "volumen" => "53" "paginaInicial" => "1204" "paginaFinal" => "1211" "link" => array:1 [ …1] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0785" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s13075-021-02494-y" "Revista" => array:5 [ "tituloSerie" => "Arthritis Res Ther" "fecha" => "2021" "volumen" => "23" "paginaInicial" => "100" "link" => array:1 [ …1] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0790" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.39528" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheumatol" "fecha" => "2016" "volumen" => "68" "paginaInicial" => "1004" "paginaFinal" => "1012" "link" => array:1 [ …1] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0795" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s12890-018-0591-y" "Revista" => array:5 [ "tituloSerie" => "BMC Pulm Med" "fecha" => "2018" "volumen" => "18" "paginaInicial" => "25" "link" => array:1 [ …1] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0800" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2665-9913(20)30098-9" "Revista" => array:6 [ "tituloSerie" => "Lancet Rheumatol" "fecha" => "2020" "volumen" => "2" "paginaInicial" => "e71" "paginaFinal" => "e83" "link" => array:1 [ …1] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0805" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Using transitional changes on high-resolution computed tomography to monitor the impact of cyclophosphamide or mycophenolate mofetil on systemic sclerosis-related interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.41085" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheumatol" "fecha" => "2020" "volumen" => "72" "paginaInicial" => "316" "paginaFinal" => "325" "link" => array:1 [ …1] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0810" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1513/AnnalsATS.201802-079OC" "Revista" => array:6 [ "tituloSerie" => "Ann Am Thorac Soc" "fecha" => "2018" "volumen" => "15" "paginaInicial" => "1286" "paginaFinal" => "1295" "link" => array:1 [ …1] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0815" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/23971983211064463" "Revista" => array:6 [ "tituloSerie" => "J Scleroderma Relat Disord" "fecha" => "2022" "volumen" => "7" "paginaInicial" => "168" "paginaFinal" => "178" "link" => array:1 [ …1] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0820" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ionizing radiation, health effects and protective measures" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "fecha" => "2022" "editorial" => "WHO" ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0825" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: a prospective study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2014-205637" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2014" "volumen" => "73" "paginaInicial" => "2069" "paginaFinal" => "2073" "link" => array:1 [ …1] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0830" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effective doses in radiology and diagnostic nuclear medicine: a catalog" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1148/radiol.2481071451" "Revista" => array:6 [ "tituloSerie" => "Radiology" "fecha" => "2008" "volumen" => "248" "paginaInicial" => "254" "paginaFinal" => "263" "link" => array:1 [ …1] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0835" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estimated radiation dose associated with low-dose chest CT of average-size participants in the National Lung Screening Trial" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2214/AJR.11.6533" "Revista" => array:5 [ "tituloSerie" => "Am J Roentgenol" "fecha" => "2011" "volumen" => "197" "paginaInicial" => "1165" "paginaFinal" => "1169" ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0840" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sources and effects of ionising radiation" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2010" "editorial" => "United Nations" "editorialLocalizacion" => "New York" ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0845" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of pure and hybrid iterative reconstruction algorithms on high-resolution computed tomography in the evaluation of interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejrad.2017.06.003" "Revista" => array:7 [ "tituloSerie" => "Eur J Radiol" "fecha" => "2017" "volumen" => "93" "paginaInicial" => "243" "paginaFinal" => "251" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0850" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical practice. Lung-cancer screening with low-dose computed tomography" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMcp1404071" "Revista" => array:5 [ "tituloSerie" => "N Engl J Med" "fecha" => "2014" "volumen" => "371" "paginaInicial" => "1813" "paginaFinal" => "1820" ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0855" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ultralow dose CT for follow-up of solid pulmonary nodules: a pilot single-center study using Bland–Altman analysis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MD.0000000000012019" "Revista" => array:5 [ "tituloSerie" => "Medicine (Baltimore)" "fecha" => "2018" "volumen" => "97" "paginaInicial" => "e12019" "link" => array:1 [ …1] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0860" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pleural irregularity, a new ultrasound sign for the study of interstitial lung disease in systemic sclerosis and antisynthetase syndrome" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Clin Exp Rheumatol" "fecha" => "2015" "volumen" => "33" "numero" => "Suppl. 91" "paginaInicial" => "S136" "paginaFinal" => "S141" "link" => array:1 [ …1] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0865" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ultrasound B-lines in the evaluation of interstitial lung disease in patients with systemic sclerosis: cut-off point definition for the presence of significant pulmonary fibrosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MD.0000000000010566" "Revista" => array:5 [ "tituloSerie" => "Medicine (Baltimore)" "fecha" => "2018" "volumen" => "97" "paginaInicial" => "e0566" "link" => array:1 [ …1] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0870" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pulmonary fibrosis: tissue characterization using late-enhanced MRI compared with unenhanced anatomic high-resolution CT" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5152/dir.2016.15331" "Revista" => array:6 [ "tituloSerie" => "Diagn Interv Radiol" "fecha" => "2017" "volumen" => "23" "paginaInicial" => "106" "paginaFinal" => "111" "link" => array:1 [ …1] ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0875" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "T1 characteristics of interstitial pulmonary fibrosis on 3T MRI-a predictor of early interstitial change?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3978/j.issn.2223-4292.2016.02.02" "Revista" => array:6 [ "tituloSerie" => "Quant Imaging Med Surg" "fecha" => "2016" "volumen" => "6" "paginaInicial" => "42" "paginaFinal" => "49" "link" => array:1 [ …1] ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0880" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Defining the clinical utility of PET or PET-CT in idiopathic inflammatory myopathies: a systematic literature review" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2022.152107" "Revista" => array:5 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "2022" "volumen" => "57" "paginaInicial" => "152107" "link" => array:1 [ …1] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0885" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:8 [ "tituloSerie" => "Clin Exp Rheumatol" "fecha" => "2015" "volumen" => "33" "numero" => "Suppl. 91" "paginaInicial" => "S111" "paginaFinal" => "S116" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0890" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201903-0486OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2019" "volumen" => "200" "paginaInicial" => "1258" "paginaFinal" => "1266" "link" => array:1 [ …1] ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib0895" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2018-213708" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2019" "volumen" => "78" "paginaInicial" => "122" "paginaFinal" => "130" "link" => array:1 [ …1] ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib0900" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II)" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201709-1845OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2018" "volumen" => "197" "paginaInicial" => "644" "paginaFinal" => "652" "link" => array:1 [ …1] ] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib0905" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2020-217455" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2021" "volumen" => "80" "paginaInicial" => "219" "paginaFinal" => "227" "link" => array:1 [ …1] ] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib0910" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s13075-017-1341-x" "Revista" => array:5 [ "tituloSerie" => "Arthritis Res Ther" "fecha" => "2017" "volumen" => "19" "paginaInicial" => "122" "link" => array:1 [ …1] ] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib0915" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early detection and management of pulmonary arterial hypertension" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09059180.00005112" "Revista" => array:6 [ "tituloSerie" => "Eur Respir Rev" "fecha" => "2012" "volumen" => "21" "paginaInicial" => "306" "paginaFinal" => "312" "link" => array:1 [ …1] ] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib0920" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/13993003.00879-2022" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "2023" "volumen" => "61" "paginaInicial" => "2200879" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib0925" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.30541" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2011" "volumen" => "63" "paginaInicial" => "3522" "paginaFinal" => "3530" "link" => array:1 [ …1] ] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib0930" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reversible hypercapnic respiratory insufficiency in scleroderma caused by respiratory muscle weakness" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/arrd.1984.130.1.142" "Revista" => array:6 [ "tituloSerie" => "Am Rev Respir Dis" "fecha" => "1984" "volumen" => "130" "paginaInicial" => "142" "paginaFinal" => "144" "link" => array:1 [ …1] ] ] ] ] ] ] 68 => array:3 [ "identificador" => "bib0935" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Six-minute walk test in systemic sclerosis: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ijcard.2016.03.084" "Revista" => array:6 [ "tituloSerie" => "Int J Cardiol" "fecha" => "2016" "volumen" => "212" "paginaInicial" => "265" "paginaFinal" => "273" "link" => array:1 [ …1] ] ] ] ] ] ] 69 => array:3 [ "identificador" => "bib0940" "etiqueta" => "70" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2012.01.083" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2012" "volumen" => "60" "paginaInicial" => "1192" "paginaFinal" => "1201" "link" => array:1 [ …1] ] ] ] ] ] ] 70 => array:3 [ "identificador" => "bib0945" "etiqueta" => "71" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/1759720X211059605" "Revista" => array:3 [ "tituloSerie" => "Ther Adv Musculoskelet Dis" "fecha" => "2021" "volumen" => "13" ] ] ] ] ] ] 71 => array:3 [ "identificador" => "bib0950" "etiqueta" => "72" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm.150.2.8049830" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "1994" "volumen" => "150" "paginaInicial" => "462" "paginaFinal" => "468" "link" => array:1 [ …1] ] ] ] ] ] ] 72 => array:3 [ "identificador" => "bib0955" "etiqueta" => "73" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm.154.2.8756813" "Revista" => array:8 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "1996" "volumen" => "154" "numero" => "Pt 1" "paginaInicial" => "400" "paginaFinal" => "406" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 73 => array:3 [ "identificador" => "bib0960" "etiqueta" => "74" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of bronchoalveolar lavage in systemic sclerosis interstitial lung disease: a systematic literature review" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/ph15121584" "Revista" => array:3 [ "tituloSerie" => "Pharmaceuticals (Basel)" "fecha" => "2022" "volumen" => "15" ] ] ] ] ] ] 74 => array:3 [ "identificador" => "bib0965" "etiqueta" => "75" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200402-147OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2004" "volumen" => "170" "paginaInicial" => "904" "paginaFinal" => "910" "link" => array:1 [ …1] ] ] ] ] ] ] 75 => array:3 [ "identificador" => "bib0970" "etiqueta" => "76" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2213-2600(16)30033-9" "Revista" => array:7 [ "tituloSerie" => "Lancet Respir Med" "fecha" => "2016" "volumen" => "4" "paginaInicial" => "557" "paginaFinal" => "565" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 76 => array:3 [ "identificador" => "bib0975" "etiqueta" => "77" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of the multidisciplinary evaluation of interstitial lung diseases: systematic literature review of the current evidence and future perspectives" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fmed.2019.00246" "Revista" => array:5 [ "tituloSerie" => "Front Med (Lausanne)" "fecha" => "2019" "volumen" => "6" "paginaInicial" => "246" "link" => array:1 [ …1] ] ] ] ] ] ] 77 => array:3 [ "identificador" => "bib0980" "etiqueta" => "78" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical impact of the interstitial lung disease multidisciplinary service" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/resp.12850" "Revista" => array:6 [ "tituloSerie" => "Respirology" "fecha" => "2016" "volumen" => "21" "paginaInicial" => "1438" "paginaFinal" => "1444" "link" => array:1 [ …1] ] ] ] ] ] ] 78 => array:3 [ "identificador" => "bib0985" "etiqueta" => "79" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The impact of rheumatological evaluation in the management of patients with interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/keq233" "Revista" => array:6 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2011" "volumen" => "50" "paginaInicial" => "489" "paginaFinal" => "493" "link" => array:1 [ …1] ] ] ] ] ] ] 79 => array:3 [ "identificador" => "bib0990" "etiqueta" => "80" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predictors of progression in systemic sclerosis patients with interstitial lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/13993003.02026-2019" "Revista" => array:3 [ "tituloSerie" => "Eur Respir J" "fecha" => "2020" "volumen" => "55" ] ] ] ] ] ] 80 => array:3 [ "identificador" => "bib0995" "etiqueta" => "81" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nintedanib in progressive fibrosing interstitial lung diseases" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1908681" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2019" "volumen" => "381" "paginaInicial" => "1718" "paginaFinal" => "1727" "link" => array:1 [ …1] ] ] ] ] ] ] 81 => array:3 [ "identificador" => "bib1000" "etiqueta" => "82" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.202202-0399ST" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2022" "volumen" => "205" "paginaInicial" => "e18" "paginaFinal" => "e47" "link" => array:1 [ …1] ] ] ] ] ] ] 82 => array:3 [ "identificador" => "bib1005" "etiqueta" => "83" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.40130" "Revista" => array:7 [ "tituloSerie" => "Arthritis Rheumatol" "fecha" => "2017" "volumen" => "69" "paginaInicial" => "1670" "paginaFinal" => "1678" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 83 => array:3 [ "identificador" => "bib1010" "etiqueta" => "84" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Connective tissue disease-associated interstitial lung diseases (CTD-ILD) – report from OMERACT CTD-ILD working group" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.141182" "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2015" "volumen" => "42" "paginaInicial" => "2168" "paginaFinal" => "2171" "link" => array:1 [ …1] ] ] ] ] ] ] 84 => array:3 [ "identificador" => "bib1015" "etiqueta" => "85" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early radiographic progression of scleroderma: lung disease predicts long-term mortality" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.chest.2021.11.033" "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "2022" "volumen" => "161" …3 ] ] ] ] ] ] 85 => array:3 [ "identificador" => "bib1020" "etiqueta" => "86" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2018-213455" "Revista" => array:6 [ …6] ] ] ] ] ] 86 => array:3 [ "identificador" => "bib1025" "etiqueta" => "87" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Correlation of delta high-resolution computed tomography (HRCT) score with delta clinical variables in early systemic sclerosis (SSc) patients" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.21037/qims.2016.08.08" "Revista" => array:6 [ …6] ] ] ] ] ] 87 => array:3 [ "identificador" => "bib1030" "etiqueta" => "88" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association of anti-topoisomerase I antibodies of the IgM isotype with disease progression in anti-topoisomerase I-positive systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.41403" "Revista" => array:6 [ …6] ] ] ] ] ] 88 => array:3 [ "identificador" => "bib1035" "etiqueta" => "89" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association of symptoms of gastroesophageal reflux, esophageal dilation and progression of systemic sclerosis-related interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/acr.25070" "Revista" => array:2 [ …2] ] ] ] ] ] 89 => array:3 [ "identificador" => "bib1040" "etiqueta" => "90" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.120705" "Revista" => array:6 [ …6] ] ] ] ] ] 90 => array:3 [ "identificador" => "bib1045" "etiqueta" => "91" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2018-213201" "Revista" => array:6 [ …6] ] ] ] ] ] 91 => array:3 [ "identificador" => "bib1050" "etiqueta" => "92" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thorax-2022-219226" "Revista" => array:2 [ …2] ] ] ] ] ] 92 => array:3 [ "identificador" => "bib1055" "etiqueta" => "93" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.resinv.2012.02.001" "Revista" => array:6 [ …6] ] ] ] ] ] 93 => array:3 [ "identificador" => "bib1060" "etiqueta" => "94" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IL-6 in inflammation, immunity, and disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1101/cshperspect.a016295" "Revista" => array:3 [ …3] ] ] ] ] ] 94 => array:3 [ "identificador" => "bib1065" "etiqueta" => "95" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "MUC1 and the MUCs: a family of human mucins with impact in cancer biology" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/10408360490452040" "Revista" => array:6 [ …6] ] ] ] ] ] 95 => array:3 [ "identificador" => "bib1070" "etiqueta" => "96" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serum interleukin-6 in systemic sclerosis and its correlation with disease parameters and cardiopulmonary involvement" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejcdt.2016.02.002" "Revista" => array:7 [ …7] ] ] ] ] ] 96 => array:3 [ "identificador" => "bib1075" "etiqueta" => "97" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00004711" "Revista" => array:6 [ …6] ] ] ] ] ] 97 => array:3 [ "identificador" => "bib1080" "etiqueta" => "98" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.chest.2016.03.004" "Revista" => array:6 [ …6] ] ] ] ] ] 98 => array:3 [ "identificador" => "bib1085" "etiqueta" => "99" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Elevated circulating CA 15.3 levels in a subset of systemic sclerosis with severe lung involvement" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.134.5.645" "Revista" => array:5 [ …5] ] ] ] ] ] 99 => array:3 [ "identificador" => "bib1090" "etiqueta" => "100" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: data from two independent cohorts" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.40171" "Revista" => array:6 [ …6] ] ] ] ] ] 100 => array:3 [ "identificador" => "bib1095" "etiqueta" => "101" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High level of chemokine CCL2 is associated with lung fibrosis progression and reduced survival in two independent systemic sclerosis cohorts [abstract]" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ …3] ] ] ] ] ] 101 => array:3 [ "identificador" => "bib1100" "etiqueta" => "102" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1440-1843.2006.00834.x" "Revista" => array:5 [ …5] ] ] ] ] ] 102 => array:3 [ "identificador" => "bib1105" "etiqueta" => "103" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Carbohydrate antigen 15.3 as a serum biomarker of interstitial lung disease in systemic sclerosis patients" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejim.2013.04.004" "Revista" => array:6 [ …6] ] ] ] ] ] 103 => array:3 [ "identificador" => "bib1110" "etiqueta" => "104" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 104 => array:3 [ "identificador" => "bib1115" "etiqueta" => "105" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.120997" "Revista" => array:6 [ …6] ] ] ] ] ] 105 => array:3 [ "identificador" => "bib1120" "etiqueta" => "106" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/kev204" "Revista" => array:7 [ …7] ] ] ] ] ] 106 => array:3 [ "identificador" => "bib1125" "etiqueta" => "107" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "KL-6 but not CCL-18 is a predictor of early progression in systemic sclerosis-related interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.170518" "Revista" => array:6 [ …6] ] ] ] ] ] 107 => array:3 [ "identificador" => "bib1130" "etiqueta" => "108" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Elevated serum krebs von den lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.160339" "Revista" => array:6 [ …6] ] ] ] ] ] 108 => array:3 [ "identificador" => "bib1135" "etiqueta" => "109" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 109 => array:3 [ "identificador" => "bib1140" "etiqueta" => "110" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.080633" "Revista" => array:6 [ …6] ] ] ] ] ] 110 => array:3 [ "identificador" => "bib1145" "etiqueta" => "111" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00296-018-3987-3" "Revista" => array:6 [ …6] ] ] ] ] ] 111 => array:3 [ "identificador" => "bib1150" "etiqueta" => "112" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.120725" "Revista" => array:6 [ …6] ] ] ] ] ] 112 => array:3 [ "identificador" => "bib1155" "etiqueta" => "113" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A composite serum biomarker index for the diagnosis of systemic sclerosis interstitial lung disease: a multicentre, observational, cohort study" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.42491" "Revista" => array:2 [ …2] ] ] ] ] ] 113 => array:3 [ "identificador" => "bib1160" "etiqueta" => "114" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Circulating biomarkers of systemic sclerosis – interstitial lung disease" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/2397198319894851" "Revista" => array:7 [ …7] ] ] ] ] ] 114 => array:3 [ "identificador" => "bib1165" "etiqueta" => "115" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Left ventricular diastolic dysfunction in systemic sclerosis: clinical, immunological and survival differences in the Spanish RESCLE registry" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2022.152033" "Revista" => array:5 [ …5] ] ] ] ] ] 115 => array:3 [ "identificador" => "bib1170" "etiqueta" => "116" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High prevalence of occult left ventricular diastolic dysfunction detected by exercise stress test in systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41598-022-06400-7" "Revista" => array:5 [ …5] ] ] ] ] ] 116 => array:3 [ "identificador" => "bib1175" "etiqueta" => "117" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Left ventricular diastolic dysfunction predicts mortality in patients with systemic sclerosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2018.07.068" "Revista" => array:6 [ …6] ] ] ] ] ] 117 => array:3 [ "identificador" => "bib1180" "etiqueta" => "118" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of Scleroderma Lung Study II" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.chest.2016.11.05" "Revista" => array:6 [ …6] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack745971" "titulo" => "Acknowledgements" "texto" => "<p id="par0125" class="elsevierStylePara elsevierViewall">JLF holds a <span class="elsevierStyleGrantSponsor" id="gs1">NHMRC Postgraduate Scholarship</span><span class="elsevierStyleGrantNumber" refid="gs1">GNT2013842</span> and an <span class="elsevierStyleGrantSponsor" id="gs2">Australian Government Research Training Program Scholarship</span>. MN holds an <span class="elsevierStyleGrantSponsor" id="gs3">NHMRC Investigator Grant</span> (<span class="elsevierStyleGrantNumber" refid="gs3">GNT1176538</span>).</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/01218123/00000031000000S1/v5_202405200140/S0121812323000580/v5_202405200140/en/main.assets" "Apartado" => array:4 [ "identificador" => "95645" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Review articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/01218123/00000031000000S1/v5_202405200140/S0121812323000580/v5_202405200140/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0121812323000580?idApp=UINPBA00004N" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 9 | 1 | 10 |
2024 October | 73 | 38 | 111 |
2024 September | 133 | 68 | 201 |
2024 August | 109 | 73 | 182 |
2024 July | 145 | 48 | 193 |
2024 June | 119 | 37 | 156 |
2024 May | 50 | 19 | 69 |
2024 April | 16 | 1 | 17 |
2024 March | 81 | 19 | 100 |
2024 February | 77 | 16 | 93 |
2024 January | 120 | 17 | 137 |
2023 December | 77 | 17 | 94 |
2023 November | 21 | 8 | 29 |
2023 October | 13 | 24 | 37 |
2023 September | 17 | 13 | 30 |